Organa Colloidal Silver
Organa Colloidal Silver
Organa Colloidal Silver

Organa Colloidal Silver

Regular price
$9.95
Sale price
$8.45
Quantity must be 1 or more

What is Crystalline Nano Silver? Crystalline Nano describes the nature of the silver: silver particles which are less than 100 nanometers. Silver particles under 100 nanometers can be absorbed very quickly by the body and even through the skin. There are no salts or proteins used in our manufacturing process, ensuring that the end product is only nano sized silver particles in distilled water. Because of the purity and particle size of Organa Silver, it is a safe and effective remedy to many illnesses.

Medical Research on Colloidal Silver

In an article by scientists Alan Lansdown and Angela Williams, silver resistance in wound care is discussed and they suggest that on the basis of present knowledge, true bacterial resistance to silver is rare.

Lansdown A, Williams A.  Bacterial resistance to silver-based antibiotics.  Nurs Times.  2007 Feb 27-Mar 5; 103(9): 48-9. 

This study sought to evaluate the efficacy of a silver-based skin antiseptic against carbapenem-resistant Enterobacteriaceae (CRE).  These organisms are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics.  The results of the study suggest that colloidal silver provides antimicrobial activity against CRE on human skin.

Wiemken, T.L.et al. Efficacy of a novel skin antiseptic against carbapenem-resistant Enterobacteriaceae.  Am J Infect Control. 2015 Apr 1;43(4):380-2. doi:10.1016/j.ajic.2014.12.007. Epub 2015 Feb 7.

This study assessed the safety and efficacy of a topical colloidal silver solution for the treatment of Staphylococcus aureus biofilms in a sheep model.  The conclusion of the study was that topical colloidal silver solution has effective antibiofilm activity in Staphylococcus aureus CRS in a sheep model and appears safe.

Rajiv S, Drilling A Bassiouni A, James C, Vreugde S Wormald PJ. Topical colloidal silver as an anti-biofilm agent in a Staphylococcus aureus chronic rhinosinusitis sheep model.  Int Forum Allergy Rhinol. 2015 Apr;5(4):283-8. doi:10.1002/alr.21459. Epub 2015 Jan 30.

This study was created to determine whether colloidal silver has any direct bactericidal effects on Staphylococcus aureus (S. aureus) biofilms.  They found that colloidal silver resulted in the reduction of the Staph bacteria by 98.8% and 98.9%.

Goggin R, Jardeleza C, Wormald PJ, Vreugde S., Colloidal silver: a novel treatment for Staphylococcus aureus biofilms? Int Forum Allergy Rhinol. 2014 Mar;4(3):171-5 doi: 10.1002/air.21259. Epub 2014 Jan 15.

Nanosilver is assumed to be a new material because of the relatively recent emergence of the term "nano". However, on close inspection nanosilver materials have a long, 120-year history of relatively safe and regulated use, chiefly in the form on colloidal silver.  Historical perspective demonstrates that nanosilver has been intentionally manufactured and adopted commercially across a wide spectrum of everyday applications for many decades.  To declare nanosilver materials as "new chemicals" with "unknown properties" that are "potentially harmful" simply on the basis of a change in nomenclature to the term "nano," and ignoring the accumulated knowledge of its scientific and regulatory heritage demonstrating both safety and efficacy in a wide range of applications, would be a mistake that does not serve the public interest.

Nowack B., Krug H., Height M., 120 Years of Nanosilver History: Implications for Policy Makers. Environ. Sci. Technol. 2011, 45, 1177-1183. pubs.acs.org.

Professor Munger at the University of Utah, initiated a human ingestion safety study on a colloidal silver supplement.  The abstract for the study states that ingestion of nanosilver particles showed no negative effects on any tested system in the body.  The study included 14 day exposures to 10 ppm and up to 35 ppm (15ml/day) silver solution in a double-blind, placebo controlled cross-over phase design.  36 healthy volunteer subjects, underwent complete metabolic, blood and platelet count, urinalysis tests, sputum hyper-responsiveness and inflammation evaluation, physical examinations, vital sign measurements, and magnetic resonance imaging of the chest and abdomen at baseline and at the end of each phase.  According to the study authors, "No clinically important changes in any metabolic, hematologic, or urinalysis measure identified were determined.  No morphological (or structural) changes were detected in the lungs, heart (cardiac function) or abdominal organs.  No changes were noted in sputum relative oxygen species or in pro-inflammatory cytokines."

Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE. In vivo human time-exposure study of orally dosed commercial silver nanoparticles.  Nanomedicine. 2014 Jan;10(1):1-9. doi:10.1016/j.nano.2013.06.010. Epub 2013 Jun 28.

In this study published in the Journal of Experimental & Clinical Cancer Research, the study authors decided to test colloidal silver against human breast cancer cells.  The researchers concluded, "The overall results indicated that the colloidal silver has antitumor activity through induction of apoptosis in MCF-7 breast cancer cell line, suggesting that colloidal silver might be a potential alternative agent for human breast cancer therapy."

Franco-Molina et al. Antitumor activity of colloidal silver on MCF-7 human breast cancer cells.  Journal of Experimental & Clinical Cancer Research 2010, 29:148